Protagonist Therapeutics, Inc vs Johnson & Johnson
PTGX vs JNJ — side-by-side comparison from reported financials. PTGX leads 4, JNJ leads 5 of 9 comparable metrics.
Protagonist Therapeutics, Inc
PTGX · Healthcare
$143.00+2.21%Strong
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | PTGX | JNJ |
|---|---|---|
| Price | $143.00 | $261.79 |
| Market cap | $9.25B | $631B |
| Revenue (TTM) | $275M | $97.9B |
| Revenue growth | +20.1% | +5.6% |
| Net margin | 30.2% | 21.5% |
| Free cash flow | $131M | $22.2B |
| Net cash (debt) | — | ($27.8B) |
| 1-year price return | +113.3% | +37.0% |
| P/E | 112.2 | 29.9 |
| P/E vs own history (cheap-side %) | 21% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | 12% | 26% |
| Altman Z-score | 139.54 | — |
| CV checks passed | 6 of 10 | 10 of 10 |
| Employees | 141 | 140,800 |
Full résumé-style profiles: PTGX CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.